TissGeneSummary for RFPL3 |
Gene summary |
Basic gene information | Gene symbol | RFPL3 |
Gene name | ret finger protein-like 3 | |
Synonyms | - | |
Cytomap | UCSC genome browser: 22q12.3 | |
Type of gene | protein-coding | |
RefGenes | NM_001098535.1, NM_006604.2, | |
Description | - | |
Modification date | 20141207 | |
dbXrefs | MIM : 605970 | |
HGNC : HGNC | ||
Ensembl : ENSG00000128276 | ||
HPRD : 09339 | ||
Vega : OTTHUMG00000030290 | ||
Protein | UniProt: go to UniProt's Cross Reference DB Table | |
Expression | CleanEX: HS_RFPL3 | |
BioGPS: 10738 | ||
Pathway | NCI Pathway Interaction Database: RFPL3 | |
KEGG: RFPL3 | ||
REACTOME: RFPL3 | ||
Pathway Commons: RFPL3 | ||
Context | iHOP: RFPL3 | |
ligand binding site mutation search in PubMed: RFPL3 | ||
UCL Cancer Institute: RFPL3 | ||
Assigned class in TissGDB* | C | |
Included tissue-specific gene expression resources | HPA,GTEx | |
Specific-tissues in normal samples (assigned by TissGDB using HPA, TiGER, and GTEx) | Testis | |
Cancer types related to the specific-tissues in cancer samples (assigned by TissGDB using TCGA) | TGCT | |
Reference showing the relevant tissue of RFPL3 | ||
Description by TissGene annotations |
* Class A consists of genes with literature evidence and is part of the cTissGenes. Class B consists of only cTissGenes without additional evidence. The remaining genes belong to Class C. |
Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez |
GO ID | GO term | PubMed ID |
Top |
TissGeneExp for RFPL3 |
Gene expressions across 28 cancer types (X-axis: cancer type and Y-axis: log2(norm_counts+1)) (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) |
Gene isoform expressions across 28 cancer types (X-axis: cancer type and Y-axis: log2(norm_counts+1)) (TCGA pan-cancer tcga_rsem_isoform_tpm, version 2016-09-01) |
Gene expressions across normal tissues of GTEx data (GTEx GTEx_Analysis_v6_RNA-seq_RNA-SeQCv1.1.8_gene_rpkm.gct) - Here, we shows the matched tissue types only among our 28 cancer types. |
Different expressions across 14 cancer types with more than 10 samples between matched tumors and normals (X-axis: cancer type and Y-axis: log2(norm_counts+1)) (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) |
- Significantly differentially expressed cancer types and information. (|Fold change|>1 and FDR<0.05) |
Cancer type | Mean(exp) in tumor | Mean(exp) in matched normal | Log2FC | P-val. | FDR |
Top |
TissGene-miRNA for RFPL3 |
Significantly anti-correlated miRNAs of TissGene across 28 cancer types (Gene-miRNA relations from TargetScanHuman Relsease 7.1, Conserved_Site_Context_Scores.txt.zip, 06.01.2016) (TCGA IlluminaHiSeq_miRNASeq, log2(RPM+1) data, version 2016-11-21) (TCGA IlluminaHiSeq_RNASeqV2, log2(normalized_count+1) data, version 2016-08-16) (Spearman’s Rank Correlation (p-value<0.05 and coefficient<-0.25)) |
Cancer type | miRNA id | miRNA accession | P-val. | Coeff. | # samples |
Top |
TissGeneMut for RFPL3 |
TissGeneSNV for RFPL3 |
nsSNV counts per each loci. Different colors of circles represent different cancer types. Circle size denotes number of samples. (TCGA somatic mutation (SNPs and small INDELs) data, version 2016-04-25) * Click on the image to enlarge it in a new window. |
Somatic nucleotide variants of TissGene across 28 cancer types (X-axis: cancer type and Y-axis: % of mutated samples) The numbers in parentheses are numbers of samples with mutation (nsSNVs). (TCGA somatic mutation (SNPs and small INDELs) data, version 2016-04-25) |
- nsSNVs sorted by frequency. |
AAchange | Cancer type | # samples |
p.L237F | UVM | 4 |
p.L237F | PCPG | 4 |
p.R280C | STAD | 3 |
p.S172F | SKCM | 2 |
p.S66L | STAD | 1 |
p.R240H | STAD | 1 |
p.D222N | UCEC | 1 |
p.R148* | ESCA | 1 |
p.T9N | SARC | 1 |
p.Q154* | LUSC | 1 |
p.S66L | SKCM | 1 |
p.M120K | LUAD | 1 |
p.D132N | PRAD | 1 |
p.R92W | COAD | 1 |
p.A32P | CESC | 1 |
p.R225H | HNSC | 1 |
p.S171F | SKCM | 1 |
p.S137F | SKCM | 1 |
p.G294D | HNSC | 1 |
p.L19F | SKCM | 1 |
p.E161K | BRCA | 1 |
p.H72N | LIHC | 1 |
p.D143E | LIHC | 1 |
p.C55S | UCEC | 1 |
p.S143F | SKCM | 1 |
p.A199T | SKCM | 1 |
p.G217E | SKCM | 1 |
p.W192* | SKCM | 1 |
p.M91I | COAD | 1 |
p.Y17N | KIRP | 1 |
p.D75N | SKCM | 1 |
p.K206R | KIRP | 1 |
p.T176P | OV | 1 |
p.E48K | SKCM | 1 |
p.S166F | SKCM | 1 |
p.P20L | SARC | 1 |
p.P20S | SKCM | 1 |
p.V273I | HNSC | 1 |
p.R148Q | SARC | 1 |
p.R94W | SKCM | 1 |
p.G150E | GBM | 1 |
p.Y46N | KIRP | 1 |
p.L151R | UCEC | 1 |
p.R148Q | UCEC | 1 |
p.G246E | SKCM | 1 |
p.K104R | LUAD | 1 |
p.E76K | SKCM | 1 |
p.G205W | LUSC | 1 |
p.T153R | UCEC | 1 |
p.F248Y | LUAD | 1 |
p.S200F | SKCM | 1 |
p.Y17F | KIRP | 1 |
p.V245L | UCEC | 1 |
p.S272R | LUAD | 1 |
p.D142N | HNSC | 1 |
p.G205E | SKCM | 1 |
p.R148X | ESCA | 1 |
p.R280H | UCEC | 1 |
p.C63Y | LGG | 1 |
p.E105K | SKCM | 1 |
p.V157M | READ | 1 |
p.K62R | STAD | 1 |
p.R148Q | SKCM | 1 |
p.Y46F | KIRP | 1 |
p.P173T | LUAD | 1 |
p.S219N | LUSC | 1 |
p.P300S | LUAD | 1 |
p.W163X | SKCM | 1 |
p.K2E | SKCM | 1 |
p.D46N | SKCM | 1 |
p.A228T | SKCM | 1 |
p.L279Q | LUAD | 1 |
p.R312H | GBM | 1 |
p.D132Y | LUSC | 1 |
p.V42I | ESCA | 1 |
p.R156Q | STAD | 1 |
p.S85C | BRCA | 1 |
p.S224G | KIRC | 1 |
p.R251C | READ | 1 |
p.G223R | SKCM | 1 |
Top |
TissGeneCNV for RFPL3 |
Copy number variations of TissGene across 28 cancer types (X-axis: cancer type and Y-axis: % of CNV samples) (TCGA Gistic2_CopyNumber_Gistic2_all_data_by_genes, Gistic2 copy number data, version 2016-08-16) |
Top |
TissGeneFusions for RFPL3 |
Fusion genes including TissGene (ChimerDB 3.0, 2016-12-01 and TCGA fusion Portal 2015-12-01) |
Database | Src | Cancer type | Sample | Fusion gene | ORF | 5'-gene BP | 3'-gene BP |
Top |
TissGeneNet for RFPL3 |
Co-expressed gene networks based on protein-protein interaction data (CePIN) (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (PINA2 ppi data) |
Top |
TissGeneProg for RFPL3 |
Kaplan-Meier plots with logrank tests of overall survival (OS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image to enlarge it in a new window. |
Kaplan-Meier plots with logrank test of relapse free survival (RFS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image enlarge it in a new window. |
Forest plot of Cox proportional hazard ratio (HR) and 95% CI of overall survival (OS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image enlarge it in a new window. |
Forest plot of Cox proportional hazard ratio (HR) and 95% CI of relapse free survival (RFS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image enlarge it in a new window. |
Top |
TissGeneClin for RFPL3 |
TissGeneDrug for RFPL3 |
Drug information targeting TissGene (DrugBank Version 5.0.6, 2017-04-01) |
DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
Top |
TissGeneDisease for RFPL3 |
Disease information associated with TissGene (DisGeNet, 2016-06-01) |
Disease ID | Disease name | # pubmeds | Source |